OncoMatch/Clinical Trials/NCT06890884
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Is NCT06890884 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for lymphoma, large b-cell, diffuse.
Treatment: Zilovertamab vedotin · Rituximab · Cyclophosphamide · Doxorubicin · Rituximab Biosimilar · Prednisone · Prednisolone · Polatuzumab vedotin · Rescue Medication — Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Disease stage
Excluded: Stage ANN ARBOR STAGE I
Has Ann Arbor Stage I DLBCL [excluded]
Prior therapy
Cannot have received: stem cell transplant
Has history of stem cell/solid organ transplant
Cannot have received: solid organ transplant
Has history of stem cell/solid organ transplant
Lab requirements
Cardiac function
No clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication
Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Infirmary Cancer Care ( Site 0157) · Mobile, Alabama
- Palo Verde Cancer Specialists ( Site 0105) · Glendale, Arizona
- Genesis Cancer and Blood Institute ( Site 0193) · Hot Springs, Arkansas
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135) · Burbank, California
- Bass Medical Group ( Site 0123) · Walnut Creek, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06890884 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify